
The Termeer Foundation Delegation

25-29 March 2024



Foreword

We are inspired by the Netherlands' long and rich history of seafaring, which of course required strong fundamentals, but relied heavily on innovation and intuition. Partnering through trade informed a keen willingness to exchange ideas and collaborate. We, at the Termeer Foundation, hold dear these qualities, so abundantly rich in the Netherlands. With Henri Termeer as our North Star, his innovation, humility, connectivity, passion, and responsibility – all beautiful Dutch qualities – are our guiding principles. Our mission is committed to developing values-based leadership in biotech globally, to influence the human element in life sciences. Thank you for inspiring our work.

Over the last 5 years, we have modeled an inspiring cross-country model of collaboration for the betterment of the world. This multi-tiered partnership has sown the seeds committed to supporting the integration, collaboration, and success of biotech globally. Thank you to the Ministry of Economic Affairs and Climate Policy, the Netherlands Enterprise Agency, HollandBIO, Health-Holland, and Netherlands Innovation Network for contributing to this Mission to the Netherlands. Together we support the goals of the Netherlands Transatlantic Life Sciences Partnership and promote the successful collaboration between Massachusetts and the Netherlands biotechnology ecosystems.

As we look ahead to this week, we are sure to benefit from learning from cross-cultural and intellectual exchange. We know we will hold space for dialogue and openness. What will surely be driving us to seek and understand is the **life** in life sciences. Traveling to this wonderful country, being together, is an integral part of recognizing the **life** in life sciences. Not for one moment will we abandon our patient-centeredness, the humanity in all that we do.

We are honored and delighted to be joining you here in the Netherlands in March 2024 and look forward to a week of discovery and collaboration!



Belinda Termeer
President and Co-Founder, The Termeer Foundation



DELEGATION

The Termeer Foundation



Belinda Termeer
President, Co-Founder and
Member of Board of Directors

The Termeer Foundation is a nonprofit organization working to connect and promote the world of healthcare innovators until every patient has a cure.

We understand that bringing new treatments to patients is grueling work with a low probability of success – nearly 90% of drug candidates fail to reach the market. We believe we can improve these odds by positively impacting the human variables in healthcare.

We are committed to continuing Henri Termeer's legacy of leadership success by infusing and sustaining the pipeline of current and future leaders to increase the probability of solving healthcare's greatest challenges.

Our supports include mentoring, networking, professional development, and financial grants intended to facilitate connections, break down silos, strengthen skillsets and ultimately enable a diverse array of current and future biotech leaders who bring much-needed treatments to patients.



Catharine Smith
Executive Director



Erica Mawby-Roche
Senior Director Programs

Bi/Ond



Cinzia Silvestri
CEO and Co-Founder

Bi/ond is a biotechnology start up, established in 2017 as a spin off the prestigious Technical University of Delft (TU Delft). We provide tools to some of the top European hospitals and collaborate with a myriad of technical institutes and research centers to help them advance in their biotech research.

Every person is unique, and our medicines should reflect that as well. The Bi/ond team aims to make this reality of personalized medicine possible by developing a lab technology for more accurate drug testing and simulations of any tissue type.

Through the use of our technology, we also empower organizations with valid alternatives to the use of animals in testing. The possibilities of using tissue slices for culture, and develop 3d perfused models in our organ on chips contribute to the 3Rs guiding principles – replacement, reduction, refinement – of animal use, and a future where an animal free research is more achievable.

CILA Therapeutics



CILA THERAPEUTICS is dedicated to respiratory health and focused on innovative treatments to help patients breathe easily and protect their lungs from irreversible damage. We own 100% of the robust IP portfolio that will generate value for investors and patients through the development of:

1. First-in-class, novel, inhaled therapeutics (de-risked) for the treatment of Airway Obstructive Pulmonary Diseases (AOPD) including COPD, Bronchiectasis, severe Asthma, Cystic fibrosis, and more to address a critical unmet need for ~20 million patients in the US and > 200 million globally. Our lead candidate CIL-05 can enter clinical studies in 12 months for our first indication, Primary Ciliary Dyskinesia (PCD), an orphan genetic disease. The path to approval is clearly defined after pre-IND meetings with the FDA.

2. A co-therapy platform to improve (3X) the transfection efficiency of nucleic acid therapeutics (RNA, DNA) delivery, increasing the efficacy and safety of these therapeutics for lung diseases, including lung cancer.

CILA is led by an experienced team with a proven track record of developing and commercializing multiple drugs in the U.S., EU, and APAC.



Safia Rizvi
CEO

Mahzi Therapeutics



Mahzi is focused on treating under-served rare genetic neurodevelopmental disorders. Based on the Greek word for 'Together', Mahzi will unite patient and family groups, academic researchers, other industry members, and its internal team of experts to develop therapies for patients with these serious diseases. Our research and development efforts are focused exclusively on rare genetic neurodevelopmental disorders, a group of serious diseases with few or no treatment options. Utilizing the expertise of our team and partners, our goal is to choose the best therapeutic approach for each individual disease and to advance that potential medicine as rapidly as possible.



Yael Weiss
CEO

Massachusetts Life Science Center




The capital of scientific revolution.

The Massachusetts Life Sciences Center is an economic development and investment agency with a mission of supporting the growth and development of the life sciences in Massachusetts. Through public-private funding initiatives, the Massachusetts Life Sciences Center supports innovation, research and development, commercialization, and manufacturing activities in the fields of biopharma, medical device, diagnostics, and digital health. As a quasi-public agency, Massachusetts Life Sciences Center also offers programs that fund innovation-driven economic and workforce development initiatives in Massachusetts.



Jeanne Leclair
Acting CEO, VP of Economic
Development & Partnerships

Massachusetts Institute of Technology



Freddy Nguyen
Director, MIT Catalyst
Scholars Program

The Massachusetts Institute of Technology (MIT), founded in 1861, has built an exceptional community of students, alums, faculty and staff to pursue its mission of service to the nation and the world. With ingenuity and drive at its core, the MIT community is driven by a shared purpose to make a better world through teaching, research, and innovation. MIT's motto "mens et manus" or "mind and hand" is exemplified in nearly every corner of the MIT campus and community as MIT strives to not only continue to create new knowledge but to apply that knowledge to real world problems. Through MIT's entrepreneurial culture and innovation ecosystem, MIT has been a leader in collaborating with industry and government to solve some of the world's toughest challenges and spinning out companies to scale and commercialize those solutions. MIT's global reach extends through alumni and through global initiatives such as the MIT Singapore Alliance for Research and Technology (SMART) and the MIT Hong Kong Innovation Node. According to a 2015 report, MIT alumni founded companies together would equate the world's 10th largest economy with gross annual revenues of approximately \$2 trillion.

Dr. Freddy T. Nguyen, MD, PhD is Research Fellow at Massachusetts Institute of Technology and Director of the MIT Catalyst Scholars Program. He received his BS in Chemistry and BA in Mathematics from Rice University, his MD-PhD in Physical Chemistry from the University of Illinois at Urbana-Champaign. He completed his Clinical Pathology Residency at Mount Sinai Hospital during the height of COVID-19 in New York City, helping develop assays for COVID-19 testing and antibody quantification, and the initial use of COVID-19 Convalescent Plasma in severe COVID patients, and his Transfusion Medicine Fellowship at Dartmouth. He is the CEO and co-founder of Nine Diagnostics developing nanotechnology-based and AI-enabled diagnostics platform for cancer screening and functional precision oncology. He is the co-founder of Prevented Health focused on precision addiction prevention using an LLM enabled bio-psycho-social approach for patient assessment, stratification, treatment, and care coordination and optimization. His expertise includes optics and imaging, nanotechnology, oncology, transfusion medicine, data science and informatics, healthcare innovation and entrepreneurship, health equity, and physician-scientist development. He was previously co-director of MIT Hacking Medicine, MIT COVID-19 Challenge, and MIT Hacking Racism Challenge.



Jeevan Ramapriya
Executive Director

In December 2023, the Healey-Driscoll Administration unveiled its economic development plan "[Team Massachusetts: Leading Future Generations](#)." The plan aligns the administration's economic development priorities around **Fundamentals**: Investing in the fundamentals to enable economic growth; **Talent**: Retaining and attracting the world's best talent; and **Sectors**: Supporting businesses that power that power the state's economy.

Jeevan Ramapriya is the Executive Director of the Massachusetts Office of International Trade and Investment ("MOITI") – the Commonwealth's primary foreign trade promotion agency.

In this role, Jeevan is responsible for promoting foreign direct investment into the Commonwealth, supporting export opportunities for Massachusetts' small businesses, and fostering relations with over 60+ foreign consulates and international trade agencies.

Prior to joining the Healey-Driscoll Administration, Jeevan was the Managing Director at State Street Bank and Trust Company's Regulatory, Industry and Government Affairs department where he supported public policy initiatives and led lobbying efforts at the state, federal, and international levels.

Neuroelectrics



Neuroelectrics is a Spanish company pioneer in brain stimulation and artificial intelligence technologies and therapies to alleviate neurological diseases.

The company currently offers the best-in-class non-invasive and high-definition electrical brain stimulation technology for personalized neuromodulation. By measuring and modifying brain function, they aim to restore brain health, minimize disabilities, and create a better life for patients.

Founded in 2011 and headquartered in Barcelona and Boston, Neuroelectrics distributes its products in more than 40 countries for basic neuroscience and clinical research in hundreds of universities and academic medical centers. Their vision is to create a powerful neurotechnology platform upon which verticals can be developed to improve the lives of as many people as possible.

Clinical applications are already being developed to diagnose and treat brain diseases as well as improve brain health (e.g., in epilepsy, neuropathic pain, or mood disorders) and cognitive function (e.g., memory in dementia or executive function in children with ADHD).



Ana Maiques
CEO and Co-Founder



Minmin Yen
CEO and Co-Founder

PhagePro is a Boston-based, mission-driven preclinical biotech startup committed to solving the antibiotic resistance crisis in emerging markets. Phages are viruses that target and kill bacteria, and its potential in treating diseases, most notably neglected diseases, earned phages a place on the World Economic Forum's Top 10 Emerging Technologies. Using a phages-for-all approach, we apply our model of microbiology, global health, and public policy to develop equitable relationships with critical partners and demonstrate the potential of phage in outbreak settings.

PhagePro has raised over \$4 million in grants and established four partnerships domestically and abroad. Led by CEO and co-founder Dr Minmin Yen, Ph.D., MPH, our team is committed to developing innovative phage-based treatments and building an equitable ecosystem that brings them to communities that need it the most.

Trip Goals - Cultivating relationships with investors

Here's the **profile of the investor/family office/HNWI** that is most likely to be open to the opportunity we offer:

- Long-term vision: Willing to think creatively about a different drug development model to address antibiotic resistance sustainably
 - Ability to wait longer for a return (6-7 years) to invest in an early-stage, preclinical biotech startup
- Impact first: Prioritizes access and infrastructure strengthening in emerging markets
- Higher risk tolerance: Drug development is a higher risk than other investments but has high reward

For those who may be interested in an introduction, I'd be interested in starting the conversation off with learning from their experiences in navigating drug development and/or the healthcare systems in Africa or Asia.

I like to start with an introductory meeting first to get to know each other. We have incredible grant scores from the NIH to move our cholera phage program forward and will know more in late March. We'll most likely begin fundraising with investors later this year with a Series A round to become a clinical-stage company.

QurAlis



Kasper Roet
CEO and Founder

QurAlis is built on new insights into human genetics and stem cell technology. Founded by an internationally recognized team of neurodegenerative biologists from Harvard Medical School and Harvard University, QurAlis is advancing a pipeline with therapeutic candidates that target specific components of ALS and FTD pathology and defined patient populations based on both disease-causing genetic mutation(s) and clinical biomarkers. The first validation of our platform is in conquering ALS - three antisense and small molecule programs addressing sub-forms of ALS.

Developing first- and best-in-class programs:

- Two programs in the clinic
- First efficacy biomarker readouts and three programs in the clinic in 2025
- Two proprietary platforms to enable additional therapies
 - Novel FlexASO platform for splice modulator targets
 - Only company with comprehensive TDP-43 platform
- Most programs benefitting from Orphan Drug and Breakthrough designations

Rhythm



Pioneering a **path forward**



Claudine van der Sande
VP, Head of CHI Program

Rhythm is a biopharmaceutical company dedicated to transforming the care of people living with hyperphagia and severe obesity caused by rare melanocortin-4 receptor (MC4R) pathway diseases.

siRNAgen Therapeutics



June Park
CEO

siRNAgen Therapeutics is a next-generation RNAi platform products company focused on immunology and central nervous system (CNS) diseases.

Their proprietary SAMiRNA™ platform leverages modular chemistry to overcome the challenges around delivery. SAMiRNA™ platform has been instrumental in the creation of innovative drugs such as SRN-001, which holds immense promise in treating fibrotic diseases globally.

With a firm commitment to innovation and collaboration, siRNAgen continues to push the boundaries of scientific discovery to change the lives of patients worldwide.

Interested in meeting potential investors and BD opportunities in CNS

Tevard Biosciences



Daniel Fischer
President and CEO

Tevard is pioneering tRNA therapeutics to treat rare genetic disorders and addresses key shortcomings of traditional gene therapy such as, inability to deliver a large gene, overexpression, and specificity. Founded by renowned MIT Professor and Whitehead Institute Founding Member Harvey Lodish with entrepreneurs and executives Daniel Fischer and Warren Lammert, fathers of children with Dravet syndrome, a rare and severe type of genetic epilepsy.

Tevard's lead program targets Dravet syndrome and other genetic epilepsies (DEEs). Other programs are in the field of cardiology and muscular dystrophy, the latter being partnered with Vertex Pharmaceuticals.

Thymune Therapeutics



Stan Wang
CEO and Co-Founder

Thymune Therapeutics is a biotechnology company developing a machine learning-driven thymic cell engineering platform to restore normal immune function in aging and disease.

The company's cutting-edge approach in iPSC-thymic cell manufacturing can generate off-the-shelf cells at scale. The company is developing a pipeline of therapies to treat immunodeficiencies, transplant-related, and autoimmune disorders.

Contact details organizers

Netherlands Innovation Network



Kim Tran
Attaché for Innovation,
Technology and Science

The Netherlands Innovation Network stimulates international cooperation for companies, research institutes and public authorities in the fields of innovation, technology and science. The network's activities support the implementation of government of the Netherlands' international knowledge and innovation agenda. We address national and global challenges and aim to further develop key enabling technologies through international cooperation.



Netherlands Enterprise Agency (RVO)



Maikel Walker
RVO Business Development Coach
US and Canada

Netherlands Enterprise Agency is part of the Dutch Ministry of Economic Affairs and Climate Policy. The Agency works in The Netherlands and abroad with governments, knowledge centers, international organizations and countless other partners. Netherlands Enterprise Agency implements Visitors' Programs on behalf of the Ministry of Foreign Affairs.



Netherlands Enterprise Agency



Simone Ho
RVO Project manager
Economic Missions and
Strategic Fairs

Health~Holland



Laura Duran
International Relations
Manager

Top Sector Life Sciences & Health (Health~Holland) works together with public and private parties to promote the economic opportunities of the societal theme Health & Care of the Dutch cabinet's Mission driven Top Sectors and Innovation Policy. The coalition does this on the basis of the five Health & Care missions, formulated by the Ministry of Health, Welfare and Sport.

The central mission is as follows: By 2040, all Dutch citizens will live at least five years longer in good health, while the health inequalities between the lowest and highest socioeconomic groups will have decreased by 30%. There are four underlying missions that contribute to this central mission through changes to lifestyle and living environment, offering more care in the right place and better perspectives for people with chronic diseases, lifelong disabilities and dementia. With this approach, the Netherlands seeks to effectively tackle major societal challenges. Industry can optimally respond to the economic opportunities that these challenges bring.

HollandBIO



Robbert Wever
Project Manager

HollandBIO is the Dutch biotech industry association connecting, supporting, and representing over 270 medical, agro-food, and industrial biotech companies. Our members are active in all phases of research and development and include all company sizes: start-ups, SMEs, listed companies and multinationals. Together, we strive for a society taking full advantage of the power of biotechnology in health, food and sustainability.